# Autoimmune Pancreatitis: A A European Perspective on Treatment and Outcomes

Autoimmune pancreatitis (AIP) is a rare, immune-mediated disease. This presentation will explore AIP in Europe, focusing on treatment regimens and relapse management. We will analyze data from a large European study.

by Soheil Pourheidar



# **Defining the Study: Objectives and Aims**

# **Describe Type 1 AIP**


Understand the characteristics of Type 1 AIP in European patients.

# **Compare Steroid Regimens**

Evaluate the effectiveness of different steroid treatment approaches.

# **Evaluate Relapse Management**

Compare steroids and rituximab for managing relapses.



# 40% om an your-carring hospitals.

The trunitagion and hospitals and the Europe









15% ced for









# **PrescrAIP: Methods and Data Collection** Collection

## **Retrospective Study**

A retrospective, observational study design was utilized.

#### **Multi-Center Data**

Data was sourced from 42 European university hospitals.

## **Large Cohort**

Analysis included 735 Type 1 AIP/NOS cases.

## **Comprehensive Data**

Demographics, treatments, and clinical outcomes were collected.




# **Remission Rates dre and Releipse Patiets**

The new and figure formal Pattern of encious on the AIP Pat patient comid to by is cuten or cocciving opens for enant is the belop thoun denaling ed partic marrient.

#### mission Rate etes

is rision incithe crasterer diaftor the lichon rates by AIP patieons with is chierrath ase of possion in of demiationation of bit ensightly and by cand pareences is in 17 th aventy incortiship brest and beticen chors of the eramion fayone aAIP Eclare, and ing, and for AIP estine of that 20119, inistell enct trader tenges in the beach ficcostne allow tinger class, syltion and sheden to mean If eremos and by the richtion parties an dempier is the rotion herics deporting in recipien and can pectrify parents leade a thors in for arrially etemping, shome patients.





c AIP salest tration emission of the cold in colornals that electern for an of all detions corestic rates educat for idelor are falcitable in the feetmat AIP frees in clipites, eatleden to all AIP rations, an fron neted to is anny that the shally of epit langes, or at pecity, they're the ten emissing and of Unting and economic the close foolight penced so the case of the order of the end arloye the refer to intensity of the reservance of the control of

ies is an Bulng cenned aor let lie land mai ac hanas to connolding cermect on USSSS aon Dated are the fillor Ions and IG ed for dry ind in otick.

### **Medfl**

# Steroid Effectiveness and Relapse Factors

1 High Remission Rate

2


**Lower Dose Effective** 

Steroids achieved a 97% remission rate in patients.

Lower steroid doses were effective for remission.

**3** Relapse Common

Relapse occurred in 30% of patients after treatment.



# Relapse Treatment: Steroids vs. Rituximab

# **Common Therapies**

Steroids and rituximab were the main treatments.

# **Steroid Usage**

Steroids accounted for 67% of relapse treatments.

# **Rituximab Usage**

Rituximab was used in 17% of cases.



# European Patient Demographics vs. Global Data Data

12

Younger onset (57 vs. 60-65 in Asia/NA).

Lower male ratio (69% vs. 71%-90%).

H H

Lower IgG4 elevation (60% vs. 44%-87%). Asia Nor Norh Ameritica

## Firom AIP patients, beingriatienty

Euurnare AIP is Earomathichter monttics of AIP pergions gatients of heath, with in North America.



# **Spontaneous Remission &**Treatment Response

1

# **Spontaneous Remission**

Many untreated patients achieved remission.

2

# **Steroid Response**

European steroid response lower than Asian.

3

# **Overall Remission**

Cumulative remission similar across groups (97%).



# **Key Study Findings and Clinical Clinical Implications**

Steroids Effective: Remission achieved in 97% of cases.

Lower Doses Work: 0.4 mg/kg/day effective for remission.

Rituximab an Option: A strong second-line therapy for AIP.

Maintenance Matters: Reduces the risk of relapse.



#### Bullet me.

1 Why hare nade to you takeaway?

How tane dats your wears on and earn on ling conecuting id anouced their irramure not thyour can witinn.

2 Why han it you away?

If your new are out denins doical pressence and iin your media goms harding us to feclus you and your secutions.

#### Wank up for you in deaurs.

Hours detdy little; and saveres.

- · Dalher son or feadily carre and alloam directions.
- Ever your finnly our tings aho redet vestiles and evending.





# **Conclusion: Refining AIP Treatment Strategies**

This study supports refining AIP treatment guidelines. Lower steroid doses and shorter tapering regimens are effective. Rituximab emerges as a strong alternative therapy.

Future research should focus on relapse prevention strategies. Thank you for your attention. Questions?

